To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

Release Date: 28/06/2017 17:00
Code(s): MEI     PDF:  
Wrap Text
Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

Mediclinic International PLC
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or the "Company")

28 June 2017

Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

On 26 June 2017, Jurgens Myburgh, Chief Financial Officer, acquired 16,000 shares in the Company
at a weighted average price per share of ZAR 123.97. Accordingly, Mr Myburgh now owns a total of
30,000 shares in Mediclinic International plc.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.


NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1. Details of PDMR / person closely associated with them (“PCA”)

a) Name                     Petrus Jurgens Myburgh

2. Reason for the notification

a) Position / status        Chief Financial Officer of the Company

b) Initial notification /   Initial Notification
   amendment

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
   auction monitor

a) Name                     Mediclinic International plc

b) LEI                      2138002S5BSBIZTD5I60

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
   type of transaction; (iii) each date; and (iv) each place where transactions have been
   conducted

a) Description of the       Ordinary Shares
   financial instrument

   Identification Code      GB00B8HX8Z88

b) Nature of the            Purchase of shares
   transaction
c) Price(s) and
   volume(s)                Prices (ZAR)                        Volumes

                            123.75                              406

                            123.75                              202

                            123.75                              262

                            123.76                              602

                            123.76                              367

                            123.77                              218

                            123.78                              805

                            123.78                              4,902

                            123.78                              1,018

                            123.78                              218

                            124.12                              1,721

                            124.25                              242

                            124.25                              310

                            124.25                              142

                            124.25                              143

                            124.25                              642

                            124.25                              1,200

                            124.25                              271

                            124.25                              2,329
d) Aggregated
   information

   Aggregated volume        16,000

   Price                    ZAR 123.97 per share

e) Date of the              26 June 2017
   transaction

f) Place of the             Johannesburg Stock Exchange
   transaction



About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1
600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700
inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.

For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 28/06/2017 05:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story